Who will be the fragrant scent of the 2015 pharmaceutical merger?
Undoubtedly, the biomedical industry has become the most dynamic market in all industries in the world in the past two years, and its market vitality has even attracted many Wall Street investors. In 2013 and 2014, the amount of IPOs carried out by biopharmaceutical companies reached a record high. According to statistics, the total amount of IPO in the biomedical industry in 2014 has become the highest in nearly a decade. In response to these IPO investments, many investors have focused their attention and funding on emerging biotech companies to support a variety of new therapeutic technologies, including cancer immunotherapy. In 2015, analysts generally believe that the biopharmaceutical industry financial activities will further maintain today's enthusiasm. The difference is that the IPO will provide sufficient financial support for future mergers and acquisitions in the biomedical industry. In fact, the total amount of biopharmaceutical mergers in 2014 has reached an astonishing $220 billion. In order to further carry out the corresponding merger and acquisition plan, each biopharmaceutical giant also needs sufficient financial support. At the beginning of 2015, the merger of biomedical industry has already begun to take shape. Earlier this month, the famous biopharmaceutical company Shire announced that it would acquire NPS Pharmaceuticals for $5.2 billion to strengthen its research and development capabilities in the rare disease field. (Related reading: Acquisition of the first case in 2015! Shire 5.2 billion US dollars to acquire NPS) And looking back to 2014, Aibowei has been close to Shire to reach a multi-billion dollar merger agreement, ultimately because of the Obama administration Relevant financial interventions are finally dead. This is also an inevitable trend in the development of the biomedical industry today. First of all, with the advent of the patent cliff, the ace drugs in the hands of many biomedical giants have expired and received strong challenges from generic drugs. Secondly, with the repeated increase of the approval thresholds of drug approval authorities in various countries, the development of new drugs has become More difficult; finally, with the globalization of the pharmaceutical market, biopharmaceutical companies need to conduct larger clinical trials, and even a clinical trial will be conducted around the world. These have increased the cost of biopharmaceutical companies for drug development. At this time, through acquisition and merger, resource optimization, and the corresponding new technology has become the first choice of major biomedical giants. Therefore, it is foreseeable that in the next few years, mergers and acquisitions will be the main theme of biopharmaceutical companies. And some analysts also listed the darling of investors. For example, Juno, a pioneer in tumor immunotherapy, pioneered CAR-T therapy. Since the IPO last year, Juno's market value has soared, and by 2015 the company's total value reached $5.1 billion. In addition, with the increase in FDA support, rare drug developers have become the scent of many investors. The market for companies in these sectors, such as Sage Therapeutics Inc. (SAGE), has risen to $1.1 billion and its market capitalization has nearly doubled. In addition, BioMarin Pharmaceutical Inc. (BMRN), which has an outstanding performance in the development of rare disease drugs, has a market value of $14 billion. The company is also likely to be among the list of biopharmaceutical giants. However, another view is that the popularity of IPOs in the biopharmaceutical market has undoubtedly pushed up the valuation of biotech companies, which is a disadvantage for all potential acquirers, or will inhibit the merger and reorganization process of biotech companies. In association with China's biopharmaceutical companies, in recent years, with the development of technology and the tilt of policies, Chinese biopharmaceutical companies have begun to grow rapidly, and a number of biomedical R&D companies such as WuXi PharmaTech have been born. If we can seize this opportunity, perhaps China's biomedical industry will also usher in an explosion! Dot Safety Tape,Dot Reflective Tape,Dot C2 Reflective Tape,Self Adhesive Reflective Tape Kunshan Jieyudeng Intelligent Technology Co., Ltd. , https://www.yuhuanptapes.com